Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,678
Out of 5,182 analysts
7
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.53 | +1,533.99% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $0.49 | +1,951.70% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $9.90 | -19.19% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $28.79 | +191.77% | 1 | Aug 16, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $6.71 | +63.93% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $0.72 | +2,819.51% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $11.85 | +7,494.94% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.53
Upside: +1,533.99%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $0.49
Upside: +1,951.70%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $9.90
Upside: -19.19%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $28.79
Upside: +191.77%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $6.71
Upside: +63.93%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $0.72
Upside: +2,819.51%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $11.85
Upside: +7,494.94%